title: Efficacy of risedronate in Japanese male patients with primary osteoporosis.
abstract: OBJECTIVE
  Although osteoporosis in men previously was relatively neglected, bisphosphonates have been strongly suggested as potent therapeutic agents. However, there are few studies on the effects of risedronate in male osteoporosis, especially in Japanese with primary osteoporosis. The aim of our study was to prospectively evaluate the effects of risedronate on bone mineral density (BMD) and bone turnover in Japanese male patients.
  
  
  METHODS
  According to the therapeutic regimen, the subjects were divided into two groups (group A, 22 with risedronate; group B, 10 without risedronate). During a one-year study duration, we measured bone-specific alkaline phosphatase (BAP) and serum N-terminal telopeptide of type I collagen (NTx) every 3 months, and BMD at 7 sites by dual-energy X-ray absorptiometry every 6 months.
  
  
  METHODS
  The subjects were 32 Japanese male patients with untreated primary osteoporosis.
  
  
  RESULTS
  In group A, but not in group B, BMD was significantly increased at the lumbar spine both at 6 months and 12 months, and at the femoral neck at 12 months, compared with baseline. Likewise, in group A, but not in group B, both BAP and NTx were significantly decreased at all time points measured (3 months, 6 months, and 12 months), compared with baseline.
  
  
  CONCLUSIONS
  These results confirmed the beneficial effects of risedronate upon increasing BMD and reducing bone turnover markers in Japanese male patients with primary osteoporosis, comparable to those previously reported in postmenopausal patients with osteoporosis.
authors.affiliation: Division of Metabolic Research, Clinical Research Institute, Center for Endocrine and Metabolic Diseases, National Hospital Organization, Kyoto Medical Center, Kyoto. spdf3ea9@room.ocn.ne.jp
authors.forename: Takafumi
authors.initials: T
authors.lastname: Majima
authors.forename: Akira
authors.initials: A
authors.lastname: Shimatsu
authors.forename: Yasato
authors.initials: Y
authors.lastname: Komatsu
authors.forename: Noriko
authors.initials: N
authors.lastname: Satoh
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fukao
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ninomiya
authors.forename: Tadashi
authors.initials: T
authors.lastname: Matsumura
authors.forename: Kazuwa
authors.initials: K
authors.lastname: Nakao
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism; D024042:Collagen Type I / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005272:Femur Neck / Q000378:metabolism; D006801:Humans; D008159:Lumbar Vertebrae / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D010455:Peptides / Q000378:metabolism; D011446:Prospective Studies; D000068296:Risedronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000469:Alkaline Phosphatase; D000068296:Risedronic Acid; D012968:Etidronic Acid